Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial

201869 citationsJournal Articlehybrid Open Access

Authors

Trastuzumab does not decrease the detection rate of CTCs in HER2 nonamplified, nonmetastatic breast cancer.

Good health and well-being

Published in: Annals of Oncology

Volume 29, Issue 8, pp. 1777-1783

Field-Weighted Citation Impact: 3.78